Analysis of stage III stomach cancer using the restricted mean survival time

被引:0
|
作者
Kim, Bitna [1 ]
Lee, Minjung [1 ]
机构
[1] Kangwon Natl Univ, Dept Stat, 1 Kangwondaehak Gil, Chuncheon Si 24341, Gangwon Do, South Korea
基金
新加坡国家研究基金会;
关键词
pseudo-observations; restricted mean survival time; stomach cancer; survival analysis; LONGITUDINAL DATA-ANALYSIS; DIFFERENCE; TESTS;
D O I
10.5351/KJAS.2021.34.2.255
中图分类号
O21 [概率论与数理统计]; C8 [统计学];
学科分类号
020208 ; 070103 ; 0714 ;
摘要
The purpose of this study is to compare the effects of treatment on stage III stomach cancer data obtained from the SEER program of the National Cancer Institute and to identify the significant risk factors for the survival rates of stage III stomach cancer. Since the proportional hazards assumption was violated for treatment, we used the restricted mean survival time as an alternative to the proportional hazards model. The restricted mean survival time was estimated using pseudo-observations, and the effects of treatment were compared using a test statistic based on the estimated restricted mean survival times. We conducted the regression analysis using a generalized linear model to investigate the significant predictors for the restricted mean survival time of patients with stage III stomach cancer. We found that there was a significant difference between the restricted mean survival times of treatment groups. Age at diagnosis, race, substage, grade, tumor size, surgery, and treatment were significant predictors for the restricted mean survival time of patients with stage III stomach cancer. Surgery was the most significant predictor for increasing the restricted mean survival time of patients with stage III stomach cancer.
引用
收藏
页码:255 / 266
页数:12
相关论文
共 50 条
  • [21] Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time
    Rahmadian, Amanda Putri
    Delos Santos, Seanthel
    Parshad, Shruti
    Everest, Louis
    Cheung, Matthew C.
    Chan, Kelvin K.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (03): : 278 - +
  • [22] Sensitivity Analysis for Restricted Mean Survival Time When Survival Curves Have Divergent Tails
    Ueno, Kentaro
    Morita, Satoshi
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2023, 57 (03) : 467 - 471
  • [23] On assessing survival benefit of immunotherapy using long-term restricted mean survival time
    Horiguchi, Miki
    Tian, Lu
    Uno, Hajime
    [J]. STATISTICS IN MEDICINE, 2023, 42 (08) : 1139 - 1155
  • [24] Sensitivity Analysis for Restricted Mean Survival Time When Survival Curves Have Divergent Tails
    Kentaro Ueno
    Satoshi Morita
    [J]. Therapeutic Innovation & Regulatory Science, 2023, 57 : 467 - 471
  • [25] A Model-Independent Method to Determine Restricted Mean Survival Time in the Analysis of Survival Curves
    Andrea Messori
    Vera Damuzzo
    Laura Agnoletto
    Luca Leonardi
    Marco Chiumente
    Daniele Mengato
    [J]. SN Comprehensive Clinical Medicine, 2020, 2 (1) : 66 - 68
  • [26] Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis
    Orkaby, Ariela R.
    Rich, Michael W.
    Sun, Ryan
    Lux, Eliah
    Wei, Lee-Jen
    Kim, Dae Hyun
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2018, 66 (10) : 1987 - 1991
  • [27] Regression analysis of restricted mean survival time based on pseudo-observations
    Andersen, PK
    Hansen, MG
    Klein, JP
    [J]. LIFETIME DATA ANALYSIS, 2004, 10 (04) : 335 - 350
  • [28] Analysis of dynamic restricted mean survival time based on pseudo-observations
    Yang, Zijing
    Zhang, Chengfeng
    Hou, Yawen
    Chen, Zheng
    [J]. BIOMETRICS, 2023, 79 (04) : 3690 - 3700
  • [29] Regression Analysis of Restricted Mean Survival Time Based on Pseudo-Observations
    Per Kragh Andersen
    Mette Gerster Hansen
    John P. Klein
    [J]. Lifetime Data Analysis, 2004, 10 : 335 - 350
  • [30] Restricted mean survival time as outcome measure in advanced urothelial bladder cancer: analysis of 4 clinical studies
    Rivano, Melania
    Cancanelli, Luca
    Di Spazio, Lorenzo
    Chiumente, Marco
    Mengato, Daniele
    Messori, Andrea
    [J]. IMMUNOTHERAPY, 2021, 13 (02) : 95 - 101